PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Entry into a Material Definitive Agreement

PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

(d) Exhibits

Exhibit Number Description
1.1 Form of Underwriting Agreement (incorporated by reference to Exhibit 1.1 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the Securities and Exchange Commission (the “SEC”) on March28, 2018).
4.1 Form of Series A Warrant (incorporated by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018).
4.2 Form of Series B Warrant (incorporated by reference to Exhibit 4.8 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018).
4.3 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.7 to the Company’s Registration Statement on Form S-1, Amendment No.4, filed with the SEC on March28, 2018).
99.1 Press Release dated March29, 2018.


Pulmatrix, Inc. Exhibit
EX-99.1 2 d556634dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PULMATRIX ANNOUNCES PRICING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING LEXINGTON,…
To view the full exhibit click here

About PULMATRIX, INC. (NASDAQ:PULM)

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

An ad to help with our costs